Holen Sie sich die Stockscreener-App
1.55
6.16%
0.09
Handel nachbörslich:
1.54
-0.01
-0.65%
Schlusskurs vom Vortag:
$1.46
Offen:
$1.46
24-Stunden-Volumen:
86,912
Relative Volume:
0.69
Marktkapitalisierung:
$7.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.04M
KGV:
-0.354
EPS:
-4.3784
Netto-Cashflow:
$-6.17M
1W Leistung:
+13.14%
1M Leistung:
+28.10%
6M Leistung:
-4.91%
1J Leistung:
-36.21%
1-Tages-Spanne:
$1.445
$1.55
1-Wochen-Bereich:
$1.38
$1.55
52-Wochen-Spanne:
$0.84
$2.68
Alzamend Neuro Inc Stock (ALZN) Company Profile
Firmenname
Alzamend Neuro Inc
Sektor
Branche
Telefon
844-722-6333
Adresse
480 PEACHTREE ROAD NE, SECOND FLOOR, ATLANTA
Compare ALZN vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
1.55 | 6.90M | 0 | -7.04M | -6.17M | -4.3784 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-01 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Aktie (ALZN) Neueste Nachrichten
Alzamend Neuro (ALZN) Drops 3.5% to $1.38 as Shares Approach Key SupportBreak of Structure - dars.gov.et
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending - marketscreener.com
Alzamend Neuro secures $7.5M in initial funding tranche - Investing.com
Alzamend Neuro Secures $25 Million Preferred Stock Financing - TipRanks
Alzamend Neuro Secures Up to $25 Million Series D Preferred Financing; $7.5 Million Funded - TradingView
Alzamend Neuro Received Notice of Noncompliance - TradingView
Alzamend Neuro’s New Lithium Study Puts AL001 in the Bipolar Disorder Spotlight - TipRanks
ALZN|Alzamend Neuro Inc|Price:1.350|Chg%:+0.040 - TradingKey
Alzamend Neuro Inc reports results for the quarter ended April 30Earnings Summary - TradingView
TradingKey - TradingKey
Alzamend Neuro Inc (ALZN) Cash Flow - TradingKey
Alzamend Neuro Inc (ALZN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alzamend Neuro, Inc. Revenue Breakdown – NASDAQ:ALZN - TradingView
Alzamend Neuro Inc (ALZN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alzamend Neuro Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Alzamend Neuro Announces Passing of Board Director - The Globe and Mail
Alzamend Neuro FY 2026: Revenue $0 EPS $(2.63) — 10-K Summary - TradingView
ALZN Q2 2026 Earnings: EPS Beat of 70.46% Surprise, No Revenue Reported, Stock Rises 1.52%EPS Consistency Score - dars.gov.et
Alzamend Neuro Announces Passing of Director Fahey McGrath, Ph.D. in July 2026 – SEC 8-K Filing Details 7 - Minichart
ALZN Q2 2026 Earnings: EPS Surpasses Estimates by Wide Margin Amidst Pre-Revenue StageFiscal Year Earnings - dars.gov.et
Price to sales forward of Alzamend Neuro, Inc. – BOATS:ALZN - TradingView
ALZN Q2 2026 Earnings: Narrower-than-expected loss sparks positive market reactionFiscal Year Earnings - dars.gov.et
ALZN Q2 2026 Earnings: EPS Beat by 70% but No Revenue – Stock Jumps on SurpriseGuidance Upgrade Report - dars.gov.et
$Alzamend Neuro (ALZN.US)$ it be like that - Moomoo
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
ALZN Q4'25 Earnings: EPS estimate is (0.67) USD - TradingView
Alzamend Neuro | DEF 14A: Definitive information statements - Moomoo
Alzamend Neuro, Inc. Actuals & Estimates (NASDAQ:ALZN) - TradingView
Alzamend Neuro, Inc. Actuals & Estimates (BOATS:ALZN) - TradingView
Price to book forward of Alzamend Neuro, Inc. – NASDAQ:ALZN - TradingView
ALZN Forecast — Price Target — Prediction for 2027 - TradingView
Alzamend Neuro (ALZN) Slips 3.1% as Stock Tests Key Support at $1.19Rounding Bottom - DonanımHaber
Enterprise value to revenue forward of Alzamend Neuro, Inc. – NASDAQ:ALZN - TradingView
Price to sales forward of Alzamend Neuro, Inc. – NASDAQ:ALZN - TradingView
ALZN Q4'25 Earnings: revenue estimate is 0 USD - TradingView
ALZN Q1 2026 Earnings: Narrower-Than-Expected Loss SurprisesFiscal Year Earnings - dars.gov.et
Alzamend Neuro (ALZN) Faces Modest Pressure Amid Broader Biotech UncertaintyPrice Target - dars.gov.et
Alzamend Neuro Inc (ALZN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alzamend Neuro Inc (ALZN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alzamend Neuro Inc (ALZN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alzamend Neuro Inc (ALZN) Institutional Confidence - TradingKey
Alzamend Neuro (ALZN) Edges Lower, Tests Support Levels Amid Biotech Sector VolatilityNHNL Ratio - dars.gov.et
Alzamend Neuro Inc (ALZN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alzamend Neuro Inc (ALZN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ALZN Q1 2026 Earnings: Smaller-than-Expected Loss Drives Shares HigherEarnings Manipulation Risk - newsline.com
Alzamend Neuro, Inc. Financial Disclosures & SEC Filings - TradingView
Alzamend Neuro (ALZN) Proxy filing Summary - Quartr
ALZN Q1 2026 Earnings: Narrower-than-Expected Loss Delivers 70% Positive SurpriseEarnings Revision Downgrade - newsline.com
Alzamend Neuro Shares Dip With AL001 Trial in Focus, Cash Concerns Linger - Bez Kabli
ALZN Q1 2026 Earnings: Significant EPS Beat Driven by Narrower-than-Expected LossOne-Time Loss Impact - newsline.com
Alzamend Neuro, Inc.Common Stock (NQ: ALZN - FinancialContent
Finanzdaten der Alzamend Neuro Inc-Aktie (ALZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):